Versartis Completes $55M Series E Financing

versartisVersartis, Inc., a Redwood City, CA-based endocrine-focused biopharmaceutical company, completed a $55m Series E financing.

Five undisclosed new investors (life science investment firms) joined existing investors Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences in the round, which brought the total capital raised to $132m.

Led by Chief Executive Officer Jeffery L. Cleland, PhD, Versartis develops VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD).

The company intends to use the funds to prepare for an international Phase 3 pediatric GHD trial of VRS-317.



Related News
08/10/2013: Versartis Completes $20M Series D Financing
15/01/2013: Versartis Completes $25M Series C Financing
17/02/2011: Versartis Completes $21M Series B Financing

Join the discussion